Lonza will construct and operate the facility in Visp, Switzerland, which will produce monoclonal antibodies for the use in biologic drugs. The company has previously set up similar sites in the U.S. and Singapore, according to the report.
“Approximately 60 percent of our pipeline is made up of biologics, including monoclonal antibodies, dedicated to key disease areas such as cardiovascular, immunology and inflammation, neurology and oncology,” Philippe Luscan, executive vice president of global industrial affairs at Sanofi, said in a statement.
The deal is still pending regulatory approval. If approved, the new site will bring about 200 jobs to the area, according to a spokesman for Sanofi.
More articles on supply chain:
Why pharmacists can’t speak up when they know customers are overpaying for drugs
LCMC Health partners with The Resource Group for supply chain services
Pharma leaders, healthcare experts advocate value-based payments for drugs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
